Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Acute Myelogenous Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Conditions: Keywords
acute myelogenous leukemia, interleukin-2
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Interleukin-2
Type: Drug
Overall Status
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment

- Total WBC recovery of 500 mm3 prior to IL-2 treatment

- Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment

- Active infection controlled prior to starting IL-2 treatment

- Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment

- O2 saturation >90% prior to starting treatment

- Stable cardiopulmonary status prior to starting IL-2 treatment

- Serum creatinine < or equal to 2.0 mg/dl

- Total bilirubin and AST <3x upper limits normal

Exclusion Criteria:

- Acute Promyelocytic Leukemia

- Active thrombocytopenic bleeding

- Cardiac ejection fraction below 45%

- Pregnancy and/or lactation
Leo W. Jenkins Cancer Center
Greenville, North Carolina, United States
Status: Recruiting
Contact: Paul Walker, MD - 252-744-5386 -
Start Date
July 2006
Completion Date
June 2020
Leo W. Jenkins Cancer Center
Leo W. Jenkins Cancer Center
Record processing date processed this data on July 28, 2015 page